A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as
Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for
Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
(LA HNSCC)

IRB/UVA Tracking #
20516
Contact
Olusegun Adelaja
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Varinder Kaur
Status
OPEN TO ACCRUAL
Ages
Adult